Asset
OLVEREMBATINIB
ASCENTAGE PHARMA GROUP INTERNATIONAL AMERICAN DEPOSITORY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04126681 | phase2 | completed | 2019-10-21 | 2024-08-01 | Ascentage Pharma Group Inc. | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase |
| NCT03883100 | phase2 | unknown | 2019-04-08 | 2024-04-01 | Ascentage Pharma Group Inc. | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation |
| NCT03883087 | phase2 | unknown | 2019-04-08 | 2024-05-01 | Ascentage Pharma Group Inc. | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation |
| NCT03594422 | phase1 | recruiting | 2018-07-11 | 2027-12-01 | Ascentage Pharma Group Inc. | A Study of HQP1351 in Patients With GIST or Other Solid Tumors |
| NCT06051409 | phase3 | recruiting | 2023-08-31 | 2027-12-31 | Ascentage Pharma Group Inc. | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) |
FDA applications (0)
This company has no applications containing this asset.